Gyre Therapeutics (GYRE) vs Nuvectis Pharma (NVCT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Nuvectis Pharma (NVCT) has outperformed Gyre Therapeutics (GYRE) over the past year, gaining 251.4% versus a loss of 1.5%. Gyre Therapeutics is the larger company by market cap ($746.5 million vs $689.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GYRE | NVCT |
|---|---|---|
| Share price | $7.04 | $21.12 |
| Market cap | $746.48M | $689.44M |
| 1-day change | +4.14% | +4.92% |
| YTD return | -0.28% | +179.74% |
| 1-year return | -1.54% | +251.41% |
| 5-year return | -88.27% | — |
| Forward P/E | 117.33 | — |
| EPS (TTM) | $-0.25 | $-1.31 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.42 | $29.28 |
| 52-week low | $5.44 | $5.55 |
| Distance from 52-week high | -25.27% | -27.86% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +165.20% | +67.61% |
| Average volume | 105.93K | 215.43K |
| Shares outstanding | 106.03M | 32.64M |
| Employees | 625 | 16 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NVCT has outperformed GYRE by 253.0 percentage points over the past year.
About Gyre Therapeutics
GYRE stock →Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 625 employees
About Nuvectis Pharma
NVCT stock →Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
GYRE vs NVCT FAQ
Which is bigger, Gyre Therapeutics or Nuvectis Pharma?
Gyre Therapeutics (GYRE) is larger, with a market capitalization of $746.48M compared with $689.44M for Nuvectis Pharma (NVCT).
Which stock has performed better over the past year, GYRE or NVCT?
NVCT returned +251.41% over the past 12 months, compared with -1.54% for GYRE (price return, excluding dividends). Past performance does not predict future results.
Are Gyre Therapeutics and Nuvectis Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.